21069334

Source:http://linkedlifedata.com/resource/pubmed/id/21069334

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008838, umls-concept:C0035647, umls-concept:C0146224, umls-concept:C0205390, umls-concept:C0442120, umls-concept:C1140680, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	2011-7-26
pubmed:abstractText	Most ovarian cancers recur after first-line treatment. We studied the pharmacology, tolerability, and therapeutic potential of intraperitoneal (IP) topotecan, alone and with IP cisplatin.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/M01 RR00096
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Lactones, http://linkedlifedata.com/resource/pubmed/chemical/Topoisomerase I Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Topotecan
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1432-0843
pubmed:author	pubmed-author:AndreopoulouEleniE, pubmed-author:BlankStephanieS, pubmed-author:ChenThomasT, pubmed-author:CurtinJohnJ, pubmed-author:HochsterHowardH, pubmed-author:LiebesLeonardL, pubmed-author:MuggiaFrancoF, pubmed-author:WallachRobertR
pubmed:issnType	Electronic
pubmed:volume	68
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	457-63
pubmed:meshHeading	pubmed-meshheading:21069334-Adult, pubmed-meshheading:21069334-Aged, pubmed-meshheading:21069334-Antineoplastic Agents, pubmed-meshheading:21069334-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21069334-Ascitic Fluid, pubmed-meshheading:21069334-Cisplatin, pubmed-meshheading:21069334-Cohort Studies, pubmed-meshheading:21069334-Fallopian Tube Neoplasms, pubmed-meshheading:21069334-Female, pubmed-meshheading:21069334-Humans, pubmed-meshheading:21069334-Infusions, Parenteral, pubmed-meshheading:21069334-Lactones, pubmed-meshheading:21069334-Middle Aged, pubmed-meshheading:21069334-Neutropenia, pubmed-meshheading:21069334-Ovarian Neoplasms, pubmed-meshheading:21069334-Remission Induction, pubmed-meshheading:21069334-Stomach Neoplasms, pubmed-meshheading:21069334-Survival Analysis, pubmed-meshheading:21069334-Topoisomerase I Inhibitors, pubmed-meshheading:21069334-Topotecan
pubmed:year	2011
pubmed:articleTitle	Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
pubmed:affiliation	Department of Medical Oncology, Albert Einstein Cancer Center, Bronx, NY, USA.
pubmed:publicationType	Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I, Research Support, N.I.H., Extramural